⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GSK News
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape | DelveInsight
globenewswire.com
CLRS
MDT
PHG
BSX
BDX
BIOT
ABT
ANGI
RMAX
MRK
SNY
JNJ
BA
GSK
AZN
PFE
NVO
AMGN
VRTX
Relation Announces Expanded Collaboration with GSK
globenewswire.com
GSK
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Instituto Costarricense de Electricidad Partners with ISASecure to Accelerate Adoption of ISA/IEC 62443 Cybersecurity Standards in the Costa Rica Energy Sector
prnewswire.com
CVX
XOM
GSK
HON
JCI
TT
Transforming Bioprocessing for the Digital Age Takes Center Stage at the Bioprocessing Summit 2026
prnewswire.com
GILD
GSK
PFE
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
businesswire.com
GSK
Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight
prnewswire.com
DBVT
NVS
AQST
GSK
REGN
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
prnewswire.com
GSK
A-Alpha Bio Announces Industry-First Data Consortium to Solve AI Protein Engineering's Experimental Data Bottleneck. Founding members include GSK, Boltz, Cradle, and Dyno Therapeutics.
globenewswire.com
GSK
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
GMAB
IMUX
INO
PDSB
AZN
GSK
MRK
BIIB
EXEL
REGN
CUE
IOBT
RAPT
PRE